Libya
Tuberculosis profile
Population  2012 6.2 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.42 (0.18–0.76) 6.8 (2.9–12)
Mortality (HIV+TB only)        
Prevalence  (includes HIV+TB) 4.1 (1.9–7) 66 (31–113)
Incidence  (includes HIV+TB) 2.5 (2–2.9) 40 (33–48)
Incidence (HIV+TB only)        
Case detection, all forms (%) 63 (53–77)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 644 (42) Relapse    
Smear-negative 372 (24) Treatment after failure    
Smear-unknown / not done 0 (0) Treatment after default    
Extrapulmonary 533 (34) Other    
Other 0 (0)      
Total new 1 549   Total retreatment    
           
Other (history unknown)          
Total new and relapse 1 549   Total cases notified 1 549  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.8 2.0 0.8
Age < 15 12 49 41
Laboratories 2012
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 6.5
Drug susceptibility testing (per 5 million population) 1.6
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 59   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 59  
Retreatment    
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 549 (100)
HIV-positive TB patients 105 (7)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 3.5 (0.1–12) 32 (7.5–56)
MDR-TB cases among notified pulmonary
TB cases
36 (1–120)   (–)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases      
Patients started on MDR-TB treatment      
Financing TB control 2013
National TB programme budget (US$ millions) 1.9
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-19 Data: www.who.int/tb/data